Oral Curcumin Treatment for Cachexia Body Wasting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating body wasting associated with diseases like cachexia lack effective, widely accepted definitions and treatments, particularly for conditions such as cachexia, sarcopenia, and anorexia, with limited human studies on curcumin's efficacy in reversing body wasting.
Innovation Solution
Oral administration of curcumin in effective doses to diminish or reverse body wasting, leveraging its non-toxic and side-effect-free properties to treat conditions like cachexia, sarcopenia, and anorexia, with specific embodiments involving liposomal or micellular curcumin formulations and dosing regimens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional nutritional support is used to treat body wasting, then some partial reversal may occur, but the treatment is not fully effective and requires prescription medications with potential side effects
Solution Approach 1:
The patent applies this principle by using curcumin, a naturally occurring compound from turmeric, as a safe, non-toxic alternative to prescription medications. Curcumin can be administered orally without the severe side effects associated with conventional drugs, making it a sustainable long-term treatment option for body wasting conditions.
Solution Approach 2:
The patent utilizes liposomal encapsulation technology to change the physical and chemical parameters of curcumin delivery. By encapsulating curcumin in liposomes, the formulation improves bioavailability, stability, and targeted delivery to affected tissues, thereby enhancing treatment effectiveness while maintaining safety.
2Reliability
If curcumin is administered to treat body wasting, then body mass gain and survival rate increase, but there is a lack of credible randomized controlled human studies to confirm efficacy
Solution Approach 1:
The patent employs liposomal encapsulation as a preliminary action to enhance curcumin's bioavailability and stability before administration. This pre-processing step ensures that the active compound reaches target tissues effectively, addressing the need for proven efficacy through improved delivery mechanisms that can be validated in clinical studies.
3Loss of information
If accurate epidemiological data on body wasting prevalence is collected, then better understanding of disease burden is achieved, but changing diagnostic criteria and under-identification lead to inaccurate data
Solution Approach 1:
The patent addresses diagnostic challenges by developing a treatment approach that can be applied across multiple body wasting conditions (cachexia, sarcopenia, anorexia) regardless of specific diagnostic criteria. The liposomal curcumin formulation provides a universal therapeutic solution that can benefit patients with various underlying causes of body wasting.
Data Source
AI summary
A method of treating or alleviating symptoms of disease, disorder or condition associated body wasting in a subject, including disease, disorder or condition associated body wasting in the subject, the disorder or condition identified based on initial measures of body mass, body mass index, or a bloodstream concentration of a substance, orally administering to said subject an amount of curcumin over a period of time effective treat or alleviate the disease, disorder or condition associated body wasting, diminishing or reversing the body wasting in the subject, and assessing efficacy of treating or alleviating symptoms of the disease, disorder or condition associated with body wasting by comparing final measures of body mass, body mass index, or a bloodstream concentration of a substance after the treatment period time to the initial measures of body mass, body mass index, or bloodstream concentration of the substance.